Klassieke psychedelica: veiligheid, neveneffecten en medicatie-interacties
E. Geleyn, Kim P. C. Kuypers, Mathieu Seynaeve, Gilbert Lemmens
Tijdschrift voor Geneeskunde July 24, 2023 DOI: 10.47671/tvg.79.23.049 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Conversation Psychotherapist |
| Key findings | Classic psychedelics are non-addictive with low toxicity, but under uncontrolled conditions and without psychological support, risks such as persistent psychotic symptoms, disabling flashbacks, and increased suicidality are real, so their use to treat psychological symptoms should be strongly discouraged. |
Abstract
Classic psychedelics: safety, side effects and medication interactions Given the growing scientific and social interest in the use of classic psychedelics for psychiatric disorders, physicians are increasingly confronted with patients resorting to these drugs. To this date, treatment with classic psychedelics within a medical framework is non-existent. Patients could seek such a treatment themselves by means of a retreat under the guidance of (non-)professionals in a non-official health facility in countries where the use of these substances is legalised. They could also go ‘underground’ in countries where these substances are illegal. It is important that physicians have an open conversation with their patients in order to adequately inform them and make a risk assessment. In this article, the safety, side effects and drug interactions of classic psychedelics are reported. Classic psychedelics are non-addictive and have a low toxicity. Their use under controlled conditions reduces the risk of serious unwanted effects, such as persistent psychotic symptoms, disabling flashback phenomena or increased suicidality. Under uncontrolled conditions and in the absence of psychological support, these risks are, however, real and thus the use of these drugs to treat psychological symptoms should be strongly discouraged. Interactions with other drugs are possible. This risk should be assessed individually for each patient, depending on the medication and type of psychedelic.
Citations in the library
Cites 64
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 59 more in the library